PMID- 23814672
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130702
LR  - 20211021
IS  - 2092-7355 (Print)
IS  - 2092-7363 (Electronic)
IS  - 2092-7355 (Linking)
VI  - 5
IP  - 4
DP  - 2013 Jul
TI  - Effects of interleukin-9 blockade on chronic airway inflammation in murine asthma 
      models.
PG  - 197-206
LID - 10.4168/aair.2013.5.4.197 [doi]
AB  - PURPOSE: Asthma is a chronic inflammatory disease of the airways associated with 
      structural changes and airway remodeling. Interleukin (IL)-9 has pleiotropic 
      effects on both inflammatory cells and airway structural cells, which are 
      involved in asthma pathogenesis. We evaluated the effects of IL-9 blockade on 
      chronic airway inflammation. METHODS: Acute airway inflammation was induced in 
      Balb/c mice using aerosolized ovalbumin (OVA), whereas chronic asthma was induced 
      by OVA exposure for 5 weeks with anti-IL-9 or isotype-matched antibody (Ab) 
      treatment during the OVA challenge. Inflammatory cells in bronchoalveolar lavage 
      fluid (BALF) were counted and lung tissues were stained to detect cellular 
      infiltration, mucus deposition, and collagen accumulation. The levels of 
      interferon (IFN)-gamma, IL-4, IL-5, IL-9, IL-17, and immunoglobulin E (IgE) in BALF 
      were measured using enzyme linked immunosorbent assays, and profiles of 
      inflammatory cells and subsets of T helper (Th) cells were analyzed using flow 
      cytometry. RESULTS: IL-9, IL-17, and IFN-gamma levels were significantly increased in 
      the chronic group compared to the acute asthma group. However, the number of 
      IL-9-positive cells was not affected, with a decrease in Th17 cells in 
      OVA-challenged caspase-1 knockout mice. Numbers of eosinophils, neutrophils, B 
      cells, mast cells, and Th17 cells decreased after administration of anti-IL-9 Ab. 
      Total IgE, IL-5, IL-9, and IL-17 levels were also lower in the anti-IL-9 group. 
      CONCLUSIONS: Our results suggest that anti-IL-9 Ab treatment inhibits pulmonary 
      infiltration of inflammatory cells and cytokine production, especially IL-17. 
      These results provide a basis for the use of an anti-IL-9 Ab to combat 
      IL-17-mediated airway inflammation.
FAU - Kim, Myung Shin
AU  - Kim MS
AD  - Department of Internal Medicine, Soonchunhyang University Gumi Hospital, Gumi, 
      Korea.
FAU - Cho, Kyung-Ah
AU  - Cho KA
FAU - Cho, Young Joo
AU  - Cho YJ
FAU - Woo, So-Youn
AU  - Woo SY
LA  - eng
PT  - Journal Article
DEP - 20130307
PL  - Korea (South)
TA  - Allergy Asthma Immunol Res
JT  - Allergy, asthma & immunology research
JID - 101518382
PMC - PMC3695233
OTO - NOTNLM
OT  - Interleukin-9
OT  - T helper 17
OT  - allergic asthma
OT  - anti-interleukin-9 antibody
COIS- There are no financial or other issues that might lead to conflict of interest.
EDAT- 2013/07/03 06:00
MHDA- 2013/07/03 06:01
PMCR- 2013/07/01
CRDT- 2013/07/02 06:00
PHST- 2012/05/22 00:00 [received]
PHST- 2012/09/29 00:00 [revised]
PHST- 2012/10/24 00:00 [accepted]
PHST- 2013/07/02 06:00 [entrez]
PHST- 2013/07/03 06:00 [pubmed]
PHST- 2013/07/03 06:01 [medline]
PHST- 2013/07/01 00:00 [pmc-release]
AID - 10.4168/aair.2013.5.4.197 [doi]
PST - ppublish
SO  - Allergy Asthma Immunol Res. 2013 Jul;5(4):197-206. doi: 
      10.4168/aair.2013.5.4.197. Epub 2013 Mar 7.